US Patent

US11266681 — Compositions comprising an RNA polymerase inhibitor and cyclodextrin for treating viral infections

Method of Use · Assigned to Gilead Sciences Inc · Expires 2038-07-10 · 12y remaining

Vulnerability score 53/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects a composition containing Compound 1, cyclodextrin, and optional pH adjusting agents for treating viral infections.

USPTO Abstract

The present disclosure provides a composition comprising Compound 1, or a pharmaceutically acceptable salt thereof, cyclodextrin, and, optionally, pH adjusting agents.

Drugs covered by this patent

Veklury (remdesivir) · Gilead Sciences

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-3832`	—	Veklury

Patent Metadata

Patent number: US11266681
Jurisdiction: US
Classification: Method of Use
Expires: 2038-07-10
Drug substance claim: No
Drug product claim: No
Assignee: Gilead Sciences Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.